Arsenal Biosciences has cleared an impressive $325 million from a third-round financing that will be used to fund clinical trials of its pipeline of CAR-T therapies, trying to break new gro
Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and Bristol-Myers Squibb’s Opdivo will now be ab
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.